2,884 matches for your search in the start-up spotlight
rss
Nouscom is a private oncology company developing next generation immunotherapies. Nouscom's proprietary technology platform, Exovax, harnesses the full power of immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators. Nouscom is led by an ...
BioXpress Therapeutics SA is a privately held biotechnology company committed to developing high quality and cost-competitive biosimilars for unmet need indications such as cancer, inflammation and autoimmunity. Headquartered in Geneva, Switzerland, BioXpress Therapeutics business is focused on ...
SIGNATOPE GmbH was founded in August 2016 in Reutlingen by Thomas Joos, Hannes Planatscher, Oliver Pötz and Octavian Schatz, together with the NMI Natural and Medical Sciences Institute at the University of Tübingen. SIGNATOPE devel-ops innovative protein assays that are capable of detecting and ...
GNA Biosolutions is a private molecular diagnostics company located in Germany. Our proprietary technology, Pulse Controlled Amplification (PCA), offers a novel, ultrafast, and cost-effective molecular diagnostic platform that captures and amplifies nucleic acids from complex clinical samples. ...
1CryoBio AG is a privately held company in the field of consumables for research and medical use, located at the Technopark of Lucerne in Root D4, Switzerland. 1CryoBio AG develops, produces and markets innovative plastic labware for cryogenic storage based on Danish design and Swiss quality. The ...
The object of the company is the development and marketing of the TolerogenixX process in various severe and most severe indications. It is a cell therapy procedure, innovation and unique selling point is the specific suppression of the immune reaction in the sense of an individualized ...
Almost half of all men and one third of all women come down with cancer once in their lifetime. But: almost all kinds of cancer are remediable if diagnosed early. In the case of cervical cancer, diagnosed pre-stages are almost 100% curable. oncgnostics GmbH, a spin-off of the university hospital ...
